Business Standard

Covid-19: Remdesivir output to be doubled to 7.4 mn doses by April-end

18 new sites get DCGI consent to make antiviral used for treating Covid-19

Remdesivir, coronavirus, covid-19, drugs, medicine, health
Premium

Daily supplies have already more than doubled. From around 70,000 doses per day hitting the market as on April 10, supplies have now touched 140,000-200,000 doses per day

Sohini Das Mumbai
India’s Remdesivir shortage may be shortlived as a stock of 7.4 million doses is likely to be available by the end of this month or the first week of May, claimed sources.

The seven manufacturers who have a licence from US drug company Gilead Sciences, Inc. to make this investigational injectable drug have been given approval by the drug regulator to activate 18 new sites where they can make Remdesivir.

This will enable them to produce an additional 3.5 million doses per month, doubling the existing installed capacity of 3.8 million doses per month.

Clinical trials have shown that the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 19 2021 | 6:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com